The Next Big Company That’s Addressing Mental Health Illness and Disorders Head-on


Rapidly accelerating demand, cutting-edge technology, a massive market, solid management … all leading to accelerated revenue growth, profits and a winning addition to your portfolio.

It’s that time again…

The time where you have the rare opportunity significantly grow the value of your portfolio by an investment in our newly Featured Company MYnd Analytics (Nasdaq: MYND $0.00website). Our MedTech Insiders Team, through ongoing research and due diligence, have identified our next Featured Company in a sector that continues to be on absolute fire and is lining for a big run in 2018.

According to stat site, approximately ONE out of FIVE Americans deal with some form of mental illness. That’s staggering, but companies like our newly Featured Company are doing something about it… see below for research details.

There are many theories on what causes mental illness cases. Aside of the obvious hereditary beliefs, there have been healthy discussions that the increase use of pesticides in our foods; the increase in the number of controversial vaccinations; widespread chemicals and heavy metals in our food and water supply; increase in electronic frequencies from cell phones and mobile devices affecting our brains; concussions from sports; and PTSD caused by military combat have all had a hand in causing an increase in mental illness and disorders.

Mental illness does not have a bias toward race, gender, age, rich or poor, or profession.

Celebrities like Beyonce, Adele, Prince Harry, and others have come out publicly admitting that they have had some form of depression, anxiety or other mental health disorders.


Professional athletes like Mike Tyson, Jerry West, Terry Bradshaw, Ricky Williams and other high profile athletes have reported living and dealing with mental illness.

There’s been controversy in the theory that mental illnesses are being tied to mass shootings. A recent Los Angeles Times article highlighted a higher number of cases of mass shootings that involved individuals who had been diagnosed with a mental disorder or showed signs of mental illness prior to the attack.

Bottom line, mental illness can affect ANYONE … and based on the stats, 1 of 5 of us are affected.

Whatever the potential causes are (and can be), we do know that mental illness is widespread throughout our society and medical help is needed.

The Mental Illness Market is Growing…FAST

As we previously highlighted, approximately 1 out of 5 Americans are dealing with some form of mental illness.

THAT is an EYE-OPENING statistic. We decided to do some additional research to understand the market and what all of this means.


According to a March 2017 summary by Grand View Research, the global Behavioral Rehabilitation market size projected to be $313 Billion by 2025. This market includes substance abuse and mental illness disorders.

Key drivers identified that are to drive growth include: (1) favorable government initiatives; (2) rising number of service providers; and (3) growing awareness among patients.

With 20% of Americans having some form of mental illness, we found a stat from Statista that listed therapy areas of drug spending in 2016, and mental health drug spending came in at $17.2 Billion… AND we anticipate that will continue to GROW!

During our research of market trends, we came across an interesting article by global advisory and financial services firm BDO that talks about growth trends in the behavioral health market.

Aside from further validating the positives affects of government legislation that will drive growth in the category, the article mentions that the category is still very “fragmented and overwhelmingly dominated by small providers with no national footprint.” We interpret this as the market is still growing with no clear leaders, which presents big opportunities for emerging companies like MYnd Analytics (Nasdaq: MYND $0.00) whose cloud-based technologies will be attractive to companies who are seeking to scale nationally.

We found this interesting article from the National Institute of Mental Health that discussed the impact of technology on the future of mental health treatments. The themes of convenience, 24-hour accessibility, costing savings and data collections to support better interventions and outcomes in the article further validate the need for technology solutions to support traditional medical protocols.

With the growth of people battling mental illness, this article lists the growing of demand of mental providers. With new medical practitioners will come the need to identify and access reliable data to help scale health offerings.

As we conducted our market research on our current Featured Company MYnd Analytics (Nasdaq: MYND $0.00), it became clear to us that the mental illness and disorder market is large with compelling growth drivers. The market is seeking solutions like what MYnd Analytics has developed that can provide targeted, customized results that are cost-effective.

MYnd Analytics is garnering mindshare

Founded in 2000 with headquarters in Mission Viejo, CA, MYnd Analytics, Inc. (Nasdaq: MYND $0.00website) provides predictive analytics via its decision support tools and platform to provide objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder, and other non-psychotic disorders.

It’s developed and launched a cloud-based database platform that helps physicians analyze and check on potential drug interactions to lessen the guesswork so that they can prescribe the RIGHT MEDICATIONS to patients with mental disorders.

Here’s why we like MYnd Analytics, Inc. (Nasdaq: MYND $0.00):

  • 1.
    Experienced Management Team and Board of Directors
  • 2.
    Proprietary cloud-based platform leverages proven registry strategy
  • 3.
    Big data opportunities
  • 4.
    Roll-out of pilot program with Horizon Healthcare Services
  • 5.
    Expansion into telemedicine

Experienced Management Team and Board of Directors

Having been with the company since 2007, George C. Carpenter IV has led MYnd Analytics as its CEO 2009. During his tenure, Mr. Carpenter has overseen the company’s up-listing to the Nasdaq (Nasdaq: MYND $0.00) since and pursuit of several successful initiatives that we believe set-up MYnd for a fantastic growth trajectory for 2018 and beyond.

We found this video of an interview with Mr. Carpenter where he outlines MYnd’s business model and opportunities:


Mr. Carpenter has also worked diligently to transform the company’s leadership with additions to senior management and Board of Directors of individuals who have held leadership positions and possess business and operational experiences with world-renown companies that include Assurant, Baxter Healthcare , BNC Mortgage, Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono, Sanofi, Merck Medco Health Solutions, , and Growmark.

Click HERE for more information about the Company’s Management Team.

Click HERE for more information about the Company’s Board of Directors.

Proprietary cloud-based platform leverages proven registry strategy

Led by Brian MacDonald, MYnd’s Chief Technology Officer, the company developed and launched PEER Online® that incorporates Psychiatric Electroencephalography Evaluation Registry (PEER) as the foundation of its platform.

PEER Online® is MYnd’s cloud-based platform that “contains clinical decision support database that uses a combination of software, analytics, and clinical outcomes to provide objective, personalized data to assist physicians in the selection of appropriate medications for patients with mental disorders.”

PEER Online “uses a statistical analysis of EEG outputs and other patient information to generate PEER Reports™, which indicate the statistical likelihood of the patient’s responsiveness to classes of central nervous system (CNS) medications (i.e. antidepressants), groups (i.e. SSRI) and individual agents (i.e. fluoxetine). “


The results in PEER Reports provide a treating physician guidance to which treatments the patient will most likely respond to, and those treatments to which the patient is least likely to respond.

The company has defensible intellectual property having owned several U.S. patents and recently announced being awarded a Canadian patent.

Click HERE for more information about MYnd Analytic’s PEER Online platform.

What we found very interesting is how PEER Online leverages a registry strategy that was started back in the 1970’s to help treat pediatric cancer. Oncologists treating pediatric cancer developed a registry that helped them network and compare treatment regimens and patient outcomes, in order to advance knowledge of pediatric cancer. The registry system still exists today and has been instrumental in improving children’s cancer survival and recovery rates.

We found this article by the National Center for Biotechnology Information that discussed PEER-guided treatment offers distinct advantages over the current standard of care.

Big data opportunities

According to MYnd Analytics (Nasdaq: MYND $0.00), there are now more than 39,000 outcomes for over 11,000 unique patients in the PEER registry.

We believe that these metrics is proves and validates that medical practitioners have recognized the value of the registry, which should further position additional adoption and growth opportunities of PEER Online. Aside from helping to increase positive patient outcomes, cost efficiencies will be directly recognized due to a lowering of multiple drug prescriptions, on-going testing, and other costs associated with non-favorable patient comes.

Global consulting firm McKinsey estimates that big data analytics can enable more than $300 billion in savings per year in U.S. healthcare, two thirds of that through reductions of approximately 8% in national healthcare expenditures.


One thing we can’t help but think about is how valuable MYnd’s database can be to pharma companies and others who are pursuing commercialization of new drugs, products, and services that would be targeting mental illness and disorder category.

We can only speculate, but do believe that MYnd is uniquely positioned to further capitalize on big data opportunities with its database via licensing and collaboration agreements.

Rollout of pilot program with Horizon Healthcare Services

In its 2017 end of year review, MYnd Analytics (Nasdaq: MYND $0.00) disclosed that its “first patient enrolled in a 600-patient paid pilot with Horizon Healthcare Services, Inc. to improve patient care over trial and error medication management and to reduce total costs of care.”

The importance of the rollout of this pilot program cannot be understated.

As managed care organizations continue to seek operational costs savings across their continuum of care, companies like MYnd who possess technologies and tools that further unlock savings while improving the delivery of care will be attractive partners, and dare we say…possible acquisition targets.

You can click here to read MYnd Analytics 2017 end of year review.

Expansion into telemedicine

Given the fact that PEER Online is a cloud-based platform, it makes totally sense that it would be a compliment to telemedicine business models.

Thus, MYnd Analytics’ announcement in November 2017 to aquire tele-health company Arcadian Telepsychiatry Services, LLC should not come as a complete shock.


Arcadian Telepsychiatry Services has a network of licensed and credentialed master-level therapists and psychiatrists that provide telepsychiatry and tele-mental health services. Arcadian has a national footprint and INSTANTLY provides MYnd access to patients in 42 states.

Additionally, Arcadian’s customer base includes major health plans, health systems, and community-based organizations so it allows MYnd with additional opportunities to connect with healthcare networks that have established patient bases.

Here is the press release in its entirety announcing the Arcadian acquisition, and what it potentially means for MYnd.

We Love MYnd, because MYnd Does Matter

As MYnd Analytics (Nasdaq: MYND $0.00) CEO George C. Carpenter IV outlined in his end of year review, “2017 was a transformative year for the company as we achieved a number of important milestones.”

In our research, we believe that 2018 is setting-up to be a BIG GROWTH YEAR for the company.

Already, there have been some key developments that have caught our attention:

  • Hiring a sales team that is tasked with pursuing strong revenue growth goals

  • First patient enrolled in a 600-patient paid pilot with Horizon Healthcare Services, Inc. (who has 3.8 million patients in its network), and Horizon alone represents a $48 million potential annual market for MYnd

  • Ended 2017 fiscal year with no long term debt on its balance sheet and over $5 million of cash

  • Recently completed $2.1 million financing by company insiders which further highlights confidence from insiders

Additionally, we found a recent analysis review by Maxim Group on MYnd that set coverage with a “buy” recommendation and forecasts MYnd’s 50 day average to be $8.52.

Given MYnd Analytic’s (Nasdaq: MYND $0.00) current share price, and factoring in Maxim Group’s recent comments, we believe that a meaningful move in the share price is about to take place. We are deploying capital right alongside you and for shorter-term investors, we would be looking for a target exit price around $9.00. For longer-term investors the sky could be the limit for this Featured Company.

Don’t delay in doing your own research.

We also suggest supporting your research by combining some supporting information from ours. While performing our due diligence on MYnd Analytics (Nasdaq: MYND $0.00), we realized that these large market numbers have caused many traditional pharma and healthcare companies to continue to make investments and pursue products and services to help with the diagnosis and treatment of mental illness and disorders.

However, non-traditional pharma and healthcare companies are also getting into the game. 3 of the companies that make-up the widely used moniker “FAANG stocks – Facebook Apple Amazon Netflix Google”, Apple, Amazon and Google, have thrown their hats into the healthcare arena.


While these companies are too mature for our investment dollars it is always good to understand what the later stage companies in the segment we are deploying capital into are doing. Let’s quickly review Apple, Amazon and Alphabet (Google) …



Apple (Nasdaq: AAPL)
Market Cap: $890.64 Billion

Founded in 1977 and with headquarters, Cupertino, CA, Apple Inc. designs, manufactures, and markets mobile communication and media devices, and personal computers to consumers, and small and mid-sized businesses; and education, enterprise, and government customers worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.

As Apple launched its smartwatch, Apple Watch in 2015, as a “comprehensive health and fitness companion,” we can only speculate the future of mental illness and disorders using Apple Watch.

Imagine people being able to access and communicate instantly to a medical practitioner during their moments of anxiety, depression, fear, etc. The medical advisor could have instant access to the person’s medical stats and history and help make real-time suggestions and recommendations.

Apple has launched HealthKit, ResearchKit and CareKit to engage developers, researchers and medical practitioners with to further extend the Apple-ecosystem to 3rd party groups.

According to Harry Wang, senior research director for Parks Associate, Apple is “known to be searching for the next $100 billion opportunity, and the gigantic healthcare industry is ripe for technology disruption.”



Amazon (Nasdaq: AMZN)
Market Cap: $612.66 Billion

Founded in 1994 and headquarters in Seattle, WA,, Inc. engages in the retail sale of consumer products and subscriptions in North America and internationally. It operates through the North America, International, and Amazon Web Services (AWS) segments. The company sells merchandise and content purchased for resale from vendors, as well as those offered by third-party sellers through retail websites. Additionally, the company offers Amazon Prime, an annual membership program, which provides free shipping of various items; access to unlimited streaming of movies and TV episodes; and other services.

Widely recognized as the premier online global retailer, Amazon has successfully executed on its business model to revolutionize the shopping experience. In doing so, it has successfully built a consumer-centric engagement model that allows it to have deep insights to consumer data as it relates to purchasing behaviors and interests.

Amazon is now setting its sights in the healthcare sector. Did you see Amazon’s recent announcement on its healthcare venture with JP Morgan and Warren Buffett’s Berkshire Hathaway?

In the not so distant future, we believe that Amazon will be parlaying its big data pedigree to analyze data on a consumer’s health, and can make highly personalized recommendations on what food, supplements, and eventually… medications, that the consumer should purchase.

Leveraging a device like Amazon’s Alexa, it could also grow into tele-medicine to communicate with consumers, connect them with medical practitioners to proactively recommend preventive care, or to address a specific healthcare issue that the consumer is facing in real-time.



Alphabet (Nasdaq: GOOG)
Market Cap: $770.448 Billion

Alphabet Inc. (formerly known as Google), through its subsidiaries, provides online advertising services in the United States, the United Kingdom, and rest of the world. The company offers performance and brand advertising services. It operates through Google and Other Bets segments. The Google segment includes principal Internet products, such as Search, Ads, Commerce, Maps, YouTube, Google Cloud, Android, Chrome, and Google Play, as well as technical infrastructure and newer efforts, including Virtual Reality.

Since the launch of Google search, Alphabet has revolutionized and transformed how information is gathered, accessed and distributed among our global society. It has truly changed how we go about our daily lives with this widespread access to information and data.

And now, it’s setting its sights on healthcare.

With the launch of Google Health back in 2008, Alphabet signaled its entrée into health-related initiatives. What started out as focus on healthcare as since expanded to all things-health.

And all indications are that Alphabet will continue to be an active investor where healthcare and technology intersects. Its venture capital group, Google Ventures, has invested in editas Medicine, Foundation Medicine, Collective Health, One Medical Group, 23andMe, FitStar, Rani Therapeutics, Rodin Therapeutics, Aspire Health, Clover Health, Compass Therapeutics, TinyRx, Metabiota, Zephyr Health and many other healthcare companies.

Our research identified how Alphabet is pursuing a parallel M&A strategy where it will buy up-and-coming companies to further build upon its market position. An example of this is Google’s acquisition of Senosis Health, a Seattle-area startup whose focus was on turning smartphones into health monitoring tools. Senosis Health’s apps use a phone’s built-in sensors to perform checkups that would normally require a dedicated sensor.

We wanted to highlight Apple, Amazon and Alphabet (Google) as all 3 companies have consumer-centric businesses; have created sustainable and market leadership positions by using technology innovations and big data to enhance lives; and are now setting their sights on healthcare initiatives to improve consumers’ health.

Based on our findings, we believe that MYnd Analytics (Nasdaq: MYND $0.00) is on the cusp of great things. It’s VERY SIMILAR to when we issued our research on Qualstar (Nasdaq: QBAK) back in January 2017. At the time, the company was trading in the high $2.00’s/low $3.00’s. Just look at the chart now and imagine what your returns would be if your entry point was in January 2017. Don’t miss out on MYnd Analytics (Nasdaq: MYND $0.00).

Remember, you can’t play if you aren’t in the game. YOU MUST OWN MYnd Analytics (Nasdaq: MYND $0.00) in order to share in its projected growth.

As with any stock investment, it is crucial that you follow our stated mantra of protecting gains on your way up, up, … and away by moving your stop loss triggers as the share price appreciates.

Be wise… be Money Street Wise!

- The Money Street Health Care Trends Team


+ Leading Industry News
+ Market Trends
+ Profitable Stock Picks
… and more


Email Article

Research MYND with Your Online Broker

Dont Yet Have a Broker?

We’ve researched the Top online Brokers. Click to see who gets the Top Marks.


Now includes EVEN MORE of what you love…
Leading Industry News, Market Trends, Profitable Stock Picks and more. SIGN UP TODAY!